Geoffroy Coteur

Suggest Changes
Learn More
OBJECTIVES To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in RAPID-axSpA (NCT01087762), an ongoing Phase 3 trial in patients with axial spondyloarthritis (axSpA),(More)
INTRODUCTION The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs)(More)
BACKGROUND Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent. OBJECTIVES To evaluate the efficacy and safety of CZP in patients with plaque psoriasis. METHODS In a(More)
BACKGROUND Crohn's disease (CD) is a chronic inflammatory illness characterized by episodic abdominal pain, diarrhoea, fever, bleeding and obstruction. While the Crohn's Disease Activity Index (CDAI)(More)